Imaging the effect of Netarsudil on the eye’s drainage system in glaucoma and ocular hypertension

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this randomized, single-masked trial, about 50 adults with ocular hypertension or open-angle glaucoma will receive netarsudil or artificial tears for roughly two to three weeks. High-resolution imaging (adaptive optics gonioscopy, AS-OCT, and OCT gonioscopy) will be done at baseline and after treatment to look for changes in trabecular meshwork lamellae spacing, height, width, and Schlemm’s canal diameter. The study aims to better understand how netarsudil may alter the eye’s fluid outflow pathways. Primary outcome is change in lamellae spacing; secondary outcomes include structural measures of the trabecular meshwork, with exploratory measures of Schlemm’s canal diameter and endothelial cell counts.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18 years or older
* Diagnosis of ocular hypertension or open-angle glaucoma
* Eye examination within the past year
* For glaucoma subjects: structural (optic nerve and/or retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma
* Best-corrected visual acuity of 20/100 or better
* Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT)
* Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable)

Exclusion Criteria:

* Known intolerance to netarsudil ophthalmic solution
* Corneal scarring or active corneal disease that would interfere with imaging
* Inability to tolerate gonioscopy procedures
* Females of childbearing potential who are not using effective contraception or are not sterile
* Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion

Where it's running

• Indiana Universtiy School of Optometry
  Bloomington, Indiana, United States Recruiting

Study contacts

• Study coordinator: Brett J King, OD
• Email: kingbrj@iu.edu
• Phone: (812) 855-1344

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bimatoprost implant with SpyGlass intraocular lens vs timolol drops for cataract patients with glaucoma

  This study tests whether placing a bimatoprost implant together with a SpyGlass intraocular lens during cataract surgery controls eye pressure better than daily timolol drops in people with mild to moderate open‑angle glaucoma or ocular hypertension.

  Recruiting Phase 3 SpyGlass Pharma, Inc. · San Antonio, Texas · NCT07218796

• Combining a bimatoprost eye implant with the SpyGlass intraocular lens versus timolol eye drops for people having cataract removal

  This study will test whether placing a small bimatoprost implant with the SpyGlass intraocular lens at the time of cataract surgery better controls eye pressure than using timolol eye drops in people with mild to moderate open-angle glaucoma or ocular hypertension.

  Recruiting Phase 3 SpyGlass Pharma, Inc. · Houston, Texas · NCT07218783

• Eye-surface inflammation after replacing nightly preserved glaucoma drops with a Durysta implant

  We will try a single Durysta intracameral implant to see if cutting back nightly preserved glaucoma drops reduces eye-surface inflammation in people with open-angle glaucoma or ocular hypertension who are pseudophakic and have signs of surface damage.

  Recruiting Phase 4 University of Miami · Miami, Florida · NCT07217678

• Limbal function and tear protein changes in glaucoma

  This study tests whether glaucoma and long-term glaucoma medicines change limbal stem cell–related corneal epithelial thickness and tear proteins in people with glaucoma, ocular hypertension, or healthy adults.

  Recruiting National Taiwan University Hospital · Hsinchu · NCT07119580

• Sustained-release TimoD (timolol) implant placed during cataract surgery for glaucoma or ocular hypertension

  This trial tests whether a small TimoD timolol implant placed during cataract surgery is safe and well tolerated in people with glaucoma or ocular hypertension.

  Recruiting Phase 1/2 EyeD Pharma · Panama City · NCT07036510

• Evaluating the long-term safety and effectiveness of a modified silicone tube for glaucoma treatment

  This study is testing a new silicone tube to see if it safely helps people with glaucoma manage their eye pressure and maintain good vision over the long term.

  Recruiting Davinci LTD · Tbilisi · NCT06691555

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.